Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 3/20 | 0.47 |
| ▸ | PPARA | Q07869 | 5/20 | 0.44 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9453176 | 1.00 | HDAC1 (0.47) | HDAC1PPARAEHMT2PPARGCYP3A4 | |
| SCHEMBL21582050 | 1.00 | HDAC1 (0.47) | HDAC1PPARAEHMT2PPARGCYP3A4 | |
| SCHEMBL7447005 | 0.86 | HDAC1 (0.55) | HDAC1PPARAEHMT2PPARG | |
| SCHEMBL21584234 | 0.85 | FAAH (0.47) | HDAC1PPARAEHMT2CYP3A4TSHR | |
| SCHEMBL21584120 | 0.85 | FAAH (0.47) | HDAC1PPARAEHMT2CYP3A4TSHR | |
| SCHEMBL4309723 | 0.83 | HDAC1 (0.43) | HDAC1PPARAEHMT2 | |
| SCHEMBL28883582 | 0.82 | FAAH (0.45) | HDAC1PPARAEHMT2CYP3A4TSHR | |
| SCHEMBL28883581 | 0.82 | FAAH (0.45) | HDAC1PPARAEHMT2CYP3A4TSHR | |
| SCHEMBL5870187 | 0.82 | HDAC1 (0.36) | HDAC1PPARAPPARG | |
| SCHEMBL5870192 | 0.82 | HDAC1 (0.36) | HDAC1PPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-5078336-A | — | — | None | — | — | JP | disclosed |
| US-12630561-B2 | Tricyclic derivatives inhibitor, preparation method, and applications thereof | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2026-05-19 | — | — | US | disclosed |
| US-12624050-B2 | Three fused ring derivative-containing salt or crystal form and pharmaceutical composition thereof | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2026-05-12 | — | — | US | disclosed |
| EP-3805231-B1 | INHIBITOR CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO LTD (CN) | 2024-10-16 | — | — | EP | disclosed |
| CN-113227101-B | Salt or crystal form containing tricyclic derivative and pharmaceutical composition thereof | 上海翰森生物医药科技有限公司 | 2024-10-11 | — | — | CN | disclosed |
| CN-114835729-B | Inhibitor containing tricyclic derivatives, preparation method and application thereof | 江苏豪森药业集团有限公司 | 2024-05-31 | — | — | CN | disclosed |
| CN-112830935-B | Crystal form containing tricyclic derivative free alkali and pharmaceutical composition thereof | 上海翰森生物医药科技有限公司 | 2023-12-22 | — | — | CN | disclosed |
| CN-117229295-A | Nitrogen-containing macrocyclic compound, and preparation method and medical application thereof | 中国医药研究开发中心有限公司 | 2023-12-15 | — | — | CN | disclosed |
| CN-112789279-B | Inhibitor containing tricyclic derivatives, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2023-09-29 | — | — | CN | disclosed |
| US-20230014383-A1 | THREE FUSED RING DERIVATIVE-CONTAINING SALT OR CRYSTAL FORM AND PHARMACEUTICAL COMPOSITION THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-01-19 | — | — | US | disclosed |
| CN-112830935-A | Crystal form containing free base of tricyclic derivative and pharmaceutical composition thereof | 上海翰森生物医药科技有限公司 | 2021-05-25 | — | — | CN | disclosed |
| CN-112789279-A | Tricyclic derivative inhibitor, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2021-05-11 | — | — | CN | disclosed |
| EP-3805231-A1 | INHIBITOR CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (CN) | 2021-04-14 | — | — | EP | disclosed |
| EP-3805231-A1 | INHIBITOR CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (CN) | 2021-04-14 | — | — | EP | disclosed |
| CN-110785423-A | Tricyclic derivative inhibitor, preparation method and application thereof | 江苏豪森药业集团有限公司 | 2020-02-11 | — | — | CN | disclosed |
| WO-2020020385-A1 | TRICYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION | 上海翰森生物医药科技有限公司 | 2020-01-30 | — | — | WO | disclosed |
| WO-2020020385-A1 | TRICYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION | 上海翰森生物医药科技有限公司 | 2020-01-30 | — | — | WO | disclosed |
| WO-2019228341-A1 | INHIBITOR CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 江苏豪森药业集团有限公司 (CN) | 2019-12-05 | — | — | WO | disclosed |
| WO-2019228341-A1 | INHIBITOR CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 江苏豪森药业集团有限公司 (CN) | 2019-12-05 | — | — | WO | disclosed |
| JP-H0578336-A | OPTICALLY ACTIVE OXAZOLIDINONE DERIVATIVE AND ITS PRODUCTION | DAISO CO LTD | 1993-03-30 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230014383-A1 | THREE FUSED RING DERIVATIVE-CONTAINING SALT OR CRYSTAL FORM AND PHARMACEUTICAL COMPOSITION THEREOF | AKT2, AKT3, PIK3R5 | HDAC1 473/4885PPARA 1160/4885EHMT2 4609/4885 |
| US-12624050-B2 | Three fused ring derivative-containing salt or crystal form and pharmaceutical composition thereof | OGDH, ME1, GCDH | HDAC1 804/4885PPARA 98/4885EHMT2 4455/4885 |
| US-12630561-B2 | Tricyclic derivatives inhibitor, preparation method, and applications thereof | PIK3CA, PIK3R1, PIK3CD | HDAC1 124/4885PPARA 1780/4885EHMT2 3902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.